Illumina acquired Grail, which developed a test to detect 50 different types of cancer at an early stage. Grail shareholders will receive $3.1 billion in cash and 9.8 million shares of Illumina common stock. However, the deal is still under review by the European Commission and could be reversed. The company believes that the deal does not fall under the jurisdiction of the European Commission and has filed a relevant claim with the court. The court decision is expected by the end of the year.